The approach uses membrane-fusogenic liposomes, microscopic lipid vesicles engineered to merge with the macrophage membrane. These liposomes carry two functional components: bacteriophage-derived receptor-binding proteins, known as RBPs, and intracellular antibiotics. RBPs are molecular structures used by bacteriophages to recognize and attach to particular bacterial surfaces. Once the liposomes fuse with a macrophage, the RBPs become displayed on the cell membrane, effectively giving the immune cell a new molecular recognition system. At the same time, the antibiotic cargo is released inside the macrophage. The resulting cell is equipped both to identify a selected bacterial species at its surface and to deploy antimicrobial activity after engulfment, without requiring genetic modification of its nucleus.

The researchers first investigated whether macrophage dysfunction represents a recurring feature of severe infection rather than an isolated phenomenon. They analyzed publicly available single-cell transcriptomic datasets collected from patients with several infectious diseases and examined gene-expression patterns in macrophages from different tissues. Across these datasets, macrophages commonly showed reduced signatures associated with pathogen recognition, phagocytosis and immune coordination. The findings indicate that infection can push macrophages into a state in which they remain present but are less capable of performing their core defensive tasks. This impairment may help explain why antibiotic treatment alone can fail: drugs may reduce bacterial replication, but they cannot fully compensate for immune cells that struggle to locate, capture or eliminate the remaining pathogens.

After membrane interface engineering, the modified macrophages displayed stronger physical interactions with their target bacteria. The team used bio-atomic force microscopy to measure the mechanical contacts formed between individual cells and microbes, while quartz crystal microbalance analysis provided additional information about binding and mass changes at the interface. These experiments showed that the engineered receptor proteins reinforced the attachment between macrophages and bacteria. The stronger interaction helped the immune cells immobilize their targets and increased the likelihood that the bacteria would be internalized through phagocytosis. In effect, the researchers converted the macrophage surface into a selective capture system, improving the first physical step required for bacterial clearance.

Live-cell imaging revealed how the engineered cells behaved during this process. Rather than allowing bacteria to move freely around them, the modified macrophages rapidly trapped and slowed target organisms before engulfment. The system could be redirected toward different pathogens by exchanging the bacteriophage-derived RBPs incorporated into the liposomes. In experiments involving Klebsiella pneumoniae and Staphylococcus aureus, the macrophages showed specific recognition of the intended bacterial targets. This modularity is central to the platform’s design. Because the recognition element can be changed without rebuilding the entire cell-engineering procedure, the same general strategy could potentially be adapted to bacterial species with different surface structures, including pathogens that emerge or acquire antibiotic resistance.

The intracellular antibiotic component provides a second layer of defense. Once a bacterium is engulfed, it enters the macrophage within a membrane-bound compartment, where it may survive if the cell’s antimicrobial machinery is weakened. Delivering antibiotics directly into the macrophage cytoplasm is intended to increase the concentration of antimicrobial cargo near internalized bacteria and to compensate for defects in the host cell’s killing capacity. The combined mechanism therefore links external recognition with internal pathogen control: the engineered RBP helps the macrophage locate and capture the bacterium, while the intracellular antibiotic supports its destruction after uptake. The researchers describe this as a temporary, programmable reconfiguration of immune-cell function rather than a permanent genetic transformation.

The therapeutic effects were tested in mouse models of bacterial pneumonia and bacterial meningitis, two infections in which uncontrolled bacterial growth and inflammatory injury can rapidly compromise organ function. Animals treated with the engineered macrophages showed lower bacterial burdens, reduced tissue inflammation and improved indicators of organ performance compared with untreated controls. The cells appeared to contribute not only to direct bacterial removal but also to broader changes in the immune environment. Treatment reduced populations associated with excessive inflammatory activity, encouraged macrophage states linked to tissue repair and helped restore a more balanced local immune response. These findings are particularly relevant to infections in which immune overactivation and immune suppression occur simultaneously, creating a cycle of pathogen persistence and collateral tissue damage.

Single-cell RNA sequencing provided further evidence that the therapy influenced immune networks beyond the engineered macrophages themselves. Following treatment, macrophage populations showed improved expression of genes associated with antigen presentation, a process through which immune cells display pathogen-derived material to coordinate adaptive immunity. Signals involved in communication between immune-cell populations were also restored, while markers associated with T-cell exhaustion were reduced. The results suggest that engineered macrophages may act as immune organizers as well as bacterial scavengers. By improving antigen presentation and cellular communication, they could help reconnect innate and adaptive immune responses during the transition from uncontrolled infection to resolution. The researchers emphasize that this systems-level effect may be important in severe disease, where multiple immune compartments become dysfunctional at the same time.

Short-term safety studies produced encouraging results. Repeated administration of the engineered macrophages caused minimal detectable immunogenicity in the treated animals, and the researchers reported no significant liver, kidney or blood-related toxicity. The membrane-based design may offer a practical safety advantage because it does not introduce permanent genetic changes into the cells. It also allows the engineering process to be carried out rapidly and adjusted according to the bacterial target. However, the findings remain preclinical, and important questions must be answered before the technology can be evaluated in people. Researchers will need to determine how long the membrane-bound receptors remain functional, how engineered cells behave in human tissues, whether they can reach infected organs efficiently and how the platform performs against polymicrobial infections or bacteria with rapidly changing surface properties.

The study presents macrophage membrane engineering as a flexible alternative to conventional immune-cell modification. By combining bacteriophage-derived targeting molecules with intracellular antibiotics, the platform addresses two major barriers in severe infection: inadequate pathogen recognition and ineffective intracellular killing. Its proposed applications include infections associated with immune suppression, intracellular bacterial disease and difficult-to-access sites such as the lungs and brain. The approach could also be adapted as new receptor-binding proteins are identified, potentially creating a library of pathogen-specific immune-cell products. While further studies are needed to establish durability, large-scale manufacturing and long-term safety, the work suggests that temporarily reprogrammed macrophages could become a new class of anti-infective therapy—one that does not simply deliver another antibiotic, but actively rebuilds the host’s capacity to find, capture and eliminate dangerous bacteria.

Subject of Research: Programmable membrane engineering of macrophages for targeted antibacterial therapy

Web References: https://doi.org/10.1016/j.scib.2026.07.008

References: Science Bulletin, DOI: 10.1016/j.scib.2026.07.008

Image Credits: © Science Bulletin

Keywords

macrophages, bacterial infections, immune-cell engineering, bacteriophage receptor-binding proteins, membrane-fusogenic liposomes, intracellular antibiotics, Klebsiella pneumoniae, Staphylococcus aureus, bacterial pneumonia, bacterial meningitis, single-cell RNA sequencing, antimicrobial therapy

Helminths, a diverse group of parasitic worms including nematodes, cestodes, and trematodes, have long been recognized for their ability to subvert human immunity to establish chronic infections. However, their seroprevalence in immunosuppressed individuals, particularly those exhibiting peripheral eosinophilia—a hematologic hallmark often indicative of parasitic infection—has remained poorly characterized until now. The recent extensive cohort study spearheaded by Mewara, Sharma, Pandiarajan, and colleagues delves systematically into this nexus, employing robust serological assays designed to detect anti-helminth antibodies in patients undergoing immunosuppressive therapy.

The plethora of medical conditions that necessitate immunosuppression—organ transplantation, cancer chemotherapy, autoimmune diseases—render patients uniquely vulnerable to opportunistic infections, helminthiasis included. By meticulously analyzing blood samples from such individuals, researchers found a strikingly elevated rate of seropositivity for helminth antigens, suggesting either active or prior exposure at levels far exceeding those anticipated in the general population. Peripheral eosinophilia further served as a critical clinical marker, signifying active immunologic engagement against parasitic antigens in these compromised hosts.

This association implies a bidirectional interplay: immunosuppression may facilitate enhanced susceptibility or diminished clearance of helminthic infections, while persistent parasitic antigens may, in turn, provoke eosinophilic responses despite the dampened immune surveillance. The study emphasizes that peripheral eosinophilia, traditionally interpreted with caution in this context, should be re-evaluated as a potent clinical sign warranting thorough parasitic screening among immunosuppressed patients.

Technological advancements in serological testing were crucial to these revelations. Employing highly sensitive and specific enzyme-linked immunosorbent assays (ELISAs) tailored to distinguish between helminth species, the researchers circumvented the limitations of direct parasitological evidence, which is often elusive in immunosuppressed individuals due to atypical clinical presentations and low parasitic loads. This serodiagnostic approach permitted a broader detection spectrum, unveiling hidden reservoirs of infection that may otherwise evade clinical suspicion.

Moreover, the implications of these findings resonate deeply within clinical practice and public health strategies, especially in helminth-endemic regions where the burden of parasitic disease intersects with increasing utilization of immunosuppressive modalities. Clinicians are urged to integrate routine helminth serology into diagnostic algorithms for patients with unexplained eosinophilia, particularly those with compromised immunity. Early identification may inform targeted anthelmintic therapies that mitigate morbidity and potentially life-threatening complications, while also guiding prophylactic interventions.

Intriguingly, the research draws attention to the complex immunological milieu present in helminth-infected immunosuppressed hosts. Helminths are known to orchestrate a delicate immune modulation, often skewing host responses toward a Th2-dominated pathway that favors eosinophil activation and antibody production. This immunomodulatory effect may paradoxically lessen inflammatory tissue damage while allowing parasite persistence—a fact that complicates the clinical course and therapeutic decisions in immunosuppressed patients battling coexisting infections.

The study’s comprehensive methodology included parallel analysis of various immunosuppressive states, including those induced by pharmacological agents such as corticosteroids and biologics, as well as disease-driven immune dysfunction. The nuanced understanding developed highlights differential risks and seropositivity rates contingent on the immunosuppressive regimen and underlying pathology, offering a tailored perspective for precision medicine.

Beyond its immediate clinical impact, this investigation revitalizes interest in the epidemiological landscape of helminthiasis in modern medicine’s evolving context. As immunosuppressive therapies become more prevalent globally, particularly in aging populations and in regions endemic for helminths, the findings underscore the need for global health policies that address parasitic infections as a critical comorbidity in immunosuppressed individuals.

Importantly, the high seropositivity rates documented raise poignant questions about latent helminth infections and their potential to reactivate or exacerbate disease once immunosuppression commences. Such reactivations could precipitate severe complications including hyperinfection syndromes, which are notoriously underdiagnosed yet carry substantial mortality risks.

The study investigators advocate for multidisciplinary collaboration, integrating parasitology, immunology, and clinical medicine to unravel the latent burden of helminth infections and optimize patient outcomes. Future research trajectories include longitudinal assessments to track infection dynamics during immunosuppression, and the development of therapeutic protocols that balance immunosuppressive efficacy with parasitic control.

Furthermore, the data prompt a reevaluation of eosinophilia as a diagnostic phenomenon. Traditionally dismissed as nonspecific or secondary to allergic and drug reactions, eosinophilia in the context of immunosuppression now emerges as a sentinel signal, demanding parasitic serological evaluation rather than reflex dismissal. This paradigm shift holds promise for improving diagnostic accuracy and tailoring interventions more effectively.

The novel insights provided extend beyond the individual patient level. They illuminate the broader immunological conversations occurring at the host-parasite interface, revealing how immune impairment shifts the equilibrium that normally contains helminth infections. These findings challenge existing dogma, reframing our understanding of parasitic persistence and immune evasion in the immunosuppressed milieu.

In summary, the landmark study by Mewara et al. fundamentally advances scientific and clinical knowledge regarding helminth infections in immunosuppressed patients, particularly emphasizing the role of peripheral eosinophilia as a critical, yet underutilized, biomarker. Their work sets the stage for enhanced diagnostic vigilance, refined therapeutic strategies, and renewed research vigor aimed at mitigating the silent burden of helminthiasis in vulnerable populations worldwide.

Subject of Research: Helminth infections and their seroprevalence in immunosuppressed patients exhibiting peripheral eosinophilia.

Article Title: High Seropositivity for Helminths in Immunosuppressed Patients with Peripheral Eosinophilia.

Article References:
Mewara, A., Sharma, N., Pandiarajan, V. et al. High Seropositivity for Helminths in Immunosuppressed Patients with Peripheral Eosinophilia. Acta Parasit. 71, 16 (2026). https://doi.org/10.1007/s11686-025-01203-y

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11686-025-01203-y